ea0099p595 | Late-Breaking | ECE2024
Ahsan Masato
, Morrison Amy
, Fowkes Natasha
, Gohil Shailesh
, J Levy Miles
, Meeran Karim
, Reddy Narendra
Background: Adrenal insufficiency (AI) requires life-long glucocorticoid substitution therapy (1), and bears significant risks of infection, cardiovascular (CV) & metabolic disease burden. Historically Hydrocortisone (HC) has been the mainstay of treatment. Prednisolone is a once-daily alternative due to a longer half-life (up to 3.2 hrs). Currently, there is no discernible evidence supporting the superiority of either medication (2).Objective: To ex...